A Comparative Study for Efficacy and Safety Between 4% Hydroquinone Cream With or Without Fractional Picosecond 1,064 nm Laser for the Treatment of Dermal or Mixed Type Melasma
Primary Purpose
Picoseconds Laser, Melasma
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Fractional Picosecond 1,064 nm laser
4% hydroquinone cream
Sponsored by
About this trial
This is an interventional treatment trial for Picoseconds Laser
Eligibility Criteria
Inclusion Criteria:
- Female with melasma lesion on bilateral sides
- Age between 18-65 years
- Dermal or mixed type melasma, confirming by Wood's lamp test
- Willing to participant in this study and signed in informed consent form
Exclusion Criteria:
- Pregnancy / lactation
- Having an activity or working outside the building or unable to avoid heavy UV light
- Allergic to UV sunscreen, topical anesthetics , topical corticosteroid or hydroquinone Treatment with laser or chemical peeling within 3 months
- Treatment with Skin Lighting medication / food supplements within 4 weeks
- Currently use of topical retinoid, hydroquinone or corticosteroid within 4 weeks
- Use of whitening cream such as alpha arbutin, azelaic acid, kojic acid ascorbic acid or any cosmetics within 2 weeks
- Uncontrolled medical illness include non-skin cancers, coagulopathy
- Intra-cardiac device - pacemaker
- Photosentive conditions such as diabetes, thyroid disease, liver and kidney disease and photosensitive dermatosis
- Currently taking anticoagulant such as warfarin
- Active skin infection or acute dermatitis at testes skin sites
- Unable to follow and comply to the study protocol
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Fractional Picosecond 1,064 nm laser and 4% hydroquinone cream
4% hydroquinone cream alone
Arm Description
Outcomes
Primary Outcome Measures
Modified MASI score
Proportion of subjects with at least 50% MASI score improvement
Secondary Outcome Measures
Mexameter Melanin index
Global satisfaction score by Quartile rating scale
Quality of life by DLQI
Full Information
NCT ID
NCT03049059
First Posted
February 3, 2017
Last Updated
February 7, 2017
Sponsor
Mae Fah Luang University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03049059
Brief Title
A Comparative Study for Efficacy and Safety Between 4% Hydroquinone Cream With or Without Fractional Picosecond 1,064 nm Laser for the Treatment of Dermal or Mixed Type Melasma
Official Title
A Comparative Study for Efficacy and Safety Between 4% Hydroquinone Cream With or Without Fractional Picosecond 1,064 nm Laser for the Treatment of Dermal or Mixed Type Melasma
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
June 1, 2016 (Actual)
Primary Completion Date
December 1, 2016 (Actual)
Study Completion Date
February 1, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mae Fah Luang University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A Comparative study for Efficacy and Safety Between 4% hydroquinone cream with or without Fractional Picosecond 1,064 nm Laser for the Treatment of Dermal or Mixed Type Melasma
Detailed Description
Primary Objective:
To compare clinical efficacy by Modified MASI score between Fractional Picosecond 1,064 nm laser and daily application of 4% hydroquinone with 4% hydroquinone alone Secondary objectives
To compare the clinical endpoints of Mexameter Melanin Index, brownish spot and Ultraviolet spots by VISIATM complexion analysis, The Antera 3D® imaging technology for pigmentation, quality of life by Dermatology Life Quality Index and patient's satisfaction between Fractional Picosecond 1,064 nm laser and 4% hydroquinone with 4% hydroquinone alone
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Picoseconds Laser, Melasma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomized split face
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fractional Picosecond 1,064 nm laser and 4% hydroquinone cream
Arm Type
Experimental
Arm Title
4% hydroquinone cream alone
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Fractional Picosecond 1,064 nm laser
Intervention Description
Fractional Picosecond 1,064 nm laser and daily application with 4% hydroquinone cream
Intervention Type
Drug
Intervention Name(s)
4% hydroquinone cream
Primary Outcome Measure Information:
Title
Modified MASI score
Time Frame
The mean change from the baseline to week-12 visit
Title
Proportion of subjects with at least 50% MASI score improvement
Time Frame
from baseline to 12-week visit
Secondary Outcome Measure Information:
Title
Mexameter Melanin index
Time Frame
baseline, week 4, week 8 and week 12
Title
Global satisfaction score by Quartile rating scale
Time Frame
week 4, week 8 and week 12
Title
Quality of life by DLQI
Time Frame
at week 12
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Female with melasma lesion on bilateral sides
Age between 18-65 years
Dermal or mixed type melasma, confirming by Wood's lamp test
Willing to participant in this study and signed in informed consent form
Exclusion Criteria:
Pregnancy / lactation
Having an activity or working outside the building or unable to avoid heavy UV light
Allergic to UV sunscreen, topical anesthetics , topical corticosteroid or hydroquinone Treatment with laser or chemical peeling within 3 months
Treatment with Skin Lighting medication / food supplements within 4 weeks
Currently use of topical retinoid, hydroquinone or corticosteroid within 4 weeks
Use of whitening cream such as alpha arbutin, azelaic acid, kojic acid ascorbic acid or any cosmetics within 2 weeks
Uncontrolled medical illness include non-skin cancers, coagulopathy
Intra-cardiac device - pacemaker
Photosentive conditions such as diabetes, thyroid disease, liver and kidney disease and photosensitive dermatosis
Currently taking anticoagulant such as warfarin
Active skin infection or acute dermatitis at testes skin sites
Unable to follow and comply to the study protocol
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
7496671
Citation
Ho C, Nguyen Q, Lowe NJ, Griffin ME, Lask G. Laser resurfacing in pigmented skin. Dermatol Surg. 1995 Dec;21(12):1035-7. doi: 10.1111/j.1524-4725.1995.tb00554.x.
Results Reference
background
Citation
Weiss M, Weiss R, Lorden F, Trageser M, Beasley K. Picosecond laser for reduction of wrinkles: Long term results. Lasers Surg Med 2015; 47(S26): 24 (Abstract #68).
Results Reference
background
Learn more about this trial
A Comparative Study for Efficacy and Safety Between 4% Hydroquinone Cream With or Without Fractional Picosecond 1,064 nm Laser for the Treatment of Dermal or Mixed Type Melasma
We'll reach out to this number within 24 hrs